Consolidated Statements of Changes in Mezzanine Equity and Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Redeemable Common Stock
Beginning balance (in shares) at Dec. 31, 2023					28,628	0	0
Beginning balance at Dec. 31, 2023					$ 7,855	$ 0	$ 0
Mezzanine Equity
Issuance of convertible preferred stock (in shares)						9,250
Issuance of convertible preferred stock						$ 2,394	4,308
Preferred stock issuance costs						(102)
Accretion on convertible preferred stock					$ 3,765	$ 1,160
Accretion on redeemable common stock							$ 26
Conversion of preferred stock (in shares)					(17,149)
Conversion of preferred stock					$ (6,469)
Issuance of redeemable common stock (in shares)							750,000
Ending balance (in shares) at Dec. 31, 2024					11,479	9,250	750,000
Ending balance at Dec. 31, 2024	$ 12,937				$ 5,151	$ 3,452	$ 4,334
Beginning balance (in shares) at Dec. 31, 2023		8,797,456
Beginning balance at Dec. 31, 2023	(37,531)	$ 1	$ 218,127	$ (255,659)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion on convertible preferred stock	(4,926)		(4,926)
Accretion on redeemable common stock	(25)		(25)
Conversion of preferred stock (in shares)		2,499,848
Conversion of preferred stock	6,469		6,469
Issuance of common stock related to offering (in shares)		3,135,136
Issuance of common stock related to offering	11,601	$ 1	11,600
Common stock issuance costs	(2,266)		(2,266)
Issuance of warrants to underwriter	382		382
RSU to RSA conversion (in shares)		387,309
Issuance of common stock for restricted stock units vesting (in shares)		812,746
Issuance of common stock for employee stock purchase plan (in shares)		59,325
Issuance of common stock for employee stock purchase plan	$ 221		221
Issuance of common stock upon exercise of stock options (in shares)	33,963	33,963
Issuance of common stock upon exercise of stock options	$ 143		143
Stock-based compensation	8,717		8,717
Net loss	(12,536)			(12,536)
Ending balance (in shares) at Dec. 31, 2024		15,725,783
Ending balance at Dec. 31, 2024	(29,751)	$ 2	238,442	(268,195)
Mezzanine Equity
Forfeiture of redeemable common stock							(187,500)
Accretion on convertible preferred stock					$ 2,000	$ 1,392
Accretion on redeemable common stock							$ 84
Ending balance (in shares) at Dec. 31, 2025					11,479	9,250	562,500
Ending balance at Dec. 31, 2025	16,413				$ 7,151	$ 4,844	$ 4,418
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion on convertible preferred stock	(3,392)		(3,392)
Accretion on redeemable common stock	(84)		(84)
Conversion of preferred stock	3,579		3,579
Issuance of common stock related to offering (in shares)		4,825,400
Issuance of common stock related to offering	32,109	$ 0	32,109
Common stock issuance costs	(632)		(632)
Issuance of common stock related to warrant exchange (in shares)		5,426,429
Issuance of common stock related to warrant exchange	46,884	$ 1	46,883
Issuance of common stock for restricted stock units vesting (in shares)		418,287
Exercise of common stock warrants (in shares)		405,454
Issuance of common stock for employee stock purchase plan (in shares)		71,160
Issuance of common stock for employee stock purchase plan	$ 258		258
Issuance of common stock upon exercise of stock options (in shares)	72,913	72,913
Issuance of common stock upon exercise of stock options	$ 304		304
Stock-based compensation	9,445		9,445
Net loss	(39,678)			(39,678)
Ending balance (in shares) at Dec. 31, 2025		26,945,426
Ending balance at Dec. 31, 2025	$ 19,042	$ 3	$ 326,912	$ (307,873)